Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of lot consistency, safety, and immunogenicity of bivalent meningococcal serogroup B rLP2086 vaccine in healthy adolescents
2010-023873-20Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease and bacterial meningitis (4 arms), sponsored by Pfizer. Primary endpoint: Immune response by hSBA against 10 secondary MenB test strains. Started Aug 2011; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal diseasebacterial meningitis
Beyond the preview
Go deeper on 2010-023873-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023873-20.